GlassScriptPhysician profile
Jai Surana
NPI 1780817288
$20,081.70
in general payments reported to CMS, 2019-2025
45 companies · $5,081 in 2025
The $5,081 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $3,073 · 2021: $1,261 · 2022: $2,470 · 2023: $1,230 · 2024: $5,478 · 2025: $5,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,696 · Education: $3,100 · Travel and Lodging: $1,529 · Consulting Fee: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,695.56 |
| Education | $3,099.99 |
| Travel and Lodging | $1,529.06 |
| Consulting Fee | $1,464.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,959.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $2,183.36 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,991.17 | 2020-2025 | |
| Boston Scientific Corporation | $1,585.14 | 2019-2020 | |
| Ethicon INC. | $1,582.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,240.31 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $1,120.03 | 2019-2025 | Tezspire, Airsupra, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $722.19 | 2019-2025 | Dupixent |
| Insmed, INC. | $530.55 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $487.51 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $446.56 | 2020-2024 | Glassia |
| Inspire Medical Systems, INC. | $332.71 | 2023-2024 | Inspire |
| United Therapeutics Corporation | $215.10 | 2021-2024 | Tyvaso |
| Ani Pharmaceuticals, INC. | $196.13 | 2024-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $182.10 | 2025 | Ohtuvayre |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $173.93 | 2019-2024 | Yupelri |
| Amgen INC. | $165.49 | 2024-2025 | Tezspire |
| Harmony Biosciences LLC | $123.84 | 2022-2025 | Wakix |
| Inogen, INC. | $102.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Shire North American Group INC | $61.92 | 2019 | |
| Lilly USA, LLC | $58.01 | 2025 | Zepbound |
| Viatris Specialty LLC | $37.89 | 2025 | Yupelri |
| Medtronic, INC. | $37.57 | 2023 | Illumisite |
| Tactile Systems Technology INC | $36.57 | 2025 | Nimbl, Flexitouch Plus |
| Covidien LP | $33.05 | 2019-2020 | |
| Genentech USA, INC. | $31.56 | 2021-2022 | |
| Gilead Sciences, INC. | $29.73 | 2024-2025 | Veklury |
| Pulmonx Corporation | $29.57 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mallinckrodt Enterprises LLC | $27.44 | 2019 | |
| Baxter Healthcare | $26.43 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $25.54 | 2019 | |
| Pfizer INC. | $23.10 | 2022 | |
| Veran Medical Technologies, INC. | $19.95 | 2021 | |
| Vifor Pharma, INC. | $19.81 | 2024 | Zemaira |
| Actelion Pharmaceuticals US, INC. | $19.41 | 2023 | Opsumit |
| Circassia INC. | $19.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.78 | 2025 | |
| Sunovion Pharmaceuticals INC. | $15.70 | 2020 | |
| Resmed Corp | $15.57 | 2024 | |
| La Jolla Pharmaceutical Company | $15.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.69 | 2022 | |
| Seagen INC. | $12.90 | 2022 | |
| Merck Sharp & Dohme LLC | $12.19 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jai Surana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.